Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

Oxaliplatin 4Paclitaxel 3Capecitabine 3pembrolizumab 2fludarabine 2Trastuzumab 2S 1 (combination) 2Ramucirumab 2Polymerase Chain Reaction 2Irinotecan 2Gastric Bypass 2Fluorouracil 2Cyclophosphamide 2Biopsy 2zimberelimab 1tusamitamab ravtansine 1talazoparib 1relatlimab 1olaparib 1milademetan 1atezolizumab 1apatinib 1XELOX 1Valganciclovir 1Taxes 1Saline Solution 1Nivolumab 1Methods 1Lubricant Eye Drops 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Stomach Neoplasms × zimberelimab × Clear all
NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡